the latest data on momelotinib for mpns
Published 3 years ago • 184 plays • Length 4:15Download video MP4
Download video MP3
Similar videos
-
2:21
clinical updates on the use of momelotinib for mpns
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
4:25
update on momelotinib for myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
5:54
mielofibrosi, correggendo l’anemia con momelotinib migliorano sintomi e qualità di vita
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
21:38
drawing the line: the rationale behind blood tube collection order
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:01
latest advances in myelofibrosis treatment
-
1:28
momelotinib in 2024: how should this agent be used in mf with anemia?
-
1:04
long-term survival outcomes in pts with mf treated with momelotinib vs danazol in the momentum trial
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:06
origins and treatment options for anemia in myelofibrosis
-
1:20
overview & updates on the momentum trial comparing momelotinib and danazol in myelofibrosis
-
2:16
long-term safety of momelotinib for myelofibrosis
-
1:39
refine: updated data on navitoclax and ruxolitinib for myelofibrosis
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis